04:00 Fri 06 Nov 2020
Omega Diagnostics Gp - Exercise of Options and Total Voting Rights
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 275,865 new ordinary shares of
Application has been made to the London Stock Exchange for the 275,865 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at
After Admission, the total number of Ordinary Shares in issue will be 179,504,189 and the total number of voting rights will therefore be 179,504,189. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
Contacts:
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
|
|
|
|
|
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
Geoff Nash / Teddy Whiley (Corporate Finance) |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE